Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.

Trial Details

NCT ID
NCT05640830
Phase
PHASE1 / PHASE2
Sponsor
Kangbuk Samsung Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • HER2-positive advanced gastric cancer
  • Defined as IHC 2+, which is IHC 3+ or SISH + (or FISH) evaluated by laboratory tests. (SISH positivity is defined as the ratio of the HER2 gene cop…
  • or significant overexpression of HER2 protein on target proteomic analysis (multiple reaction monitoring)
  • Patients who have progressed in response to one systemic anticancer therapy for advanced gastric cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →